Loading
A phase 1 trial of AVC-201 run by AvenCell Europe GmbH, now recruiting.
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) is a phase 1 interventional study registered as NCT05949125 by AvenCell Europe GmbH, with 37 participants planned, started 2024-01-03. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 and Allo-RevCAR01-T.
Shares AvenCell Therapeutics and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/